ASCT2 has been targeted with shRNA and small molecular inhibitors in a broad spectrum of cancers including melanoma [20], prostate cancer [21], human head and neck squamous cell carcinoma [22], and breast cancer [23], among others. This evidence concerns the gene SLC1A5 and cancer.